Medicare ACO savings data: what a PV team can and cannot take from CMS's 2025 results
CMS reports $2.5bn net savings and 12.6m beneficiaries in the Shared Savings Program. The records contain no drug-safety content, so the relevance to pharmacovigilance is indirect.
What CMS published
On 17 November CMS issued a fact sheet on the financial and quality results of Medicare Shared Savings Program (MSSP) accountable care organisations (ACOs) for Performance Year 2025. The records available to us do not include the fact sheet's figures. We cannot report quality scores or per-ACO results.
A companion CMS press release gives the headline numbers. ACOs in the programme reached a record 12.6 million beneficiaries, and net savings to Medicare topped $2.5 billion. CMS describes this as the ninth straight year of savings.
In general terms, the MSSP lets groups of providers take shared responsibility for the cost and quality of care for a defined population of Medicare beneficiaries. They can share in savings if they meet quality requirements. Nothing in the records links these results to medicines, adverse events or safety reporting.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- CMS publishes Performance Year 2025 results for Medicare Shared Savings Program ACOs CMS · Tue 17 Nov 2026
- Medicare Shared Savings Program posts $2.5bn net savings in 2025, a ninth straight year CMS · Tue 17 Nov 2026
- AEMPS veterinary committees note 21 pharmacovigilance-driven authorisation changes and recall follow-up problems AEMPS · Tue 17 Nov 2026
- FDA classes Cardinal Health Presource kit correction as Class I over recalled BD Alaris infusion sets FDA MedWatch · Tue 17 Nov 2026
- Commission grants marketing authorisation for Revolution Medicines' daraxonrasib product Rasonque European Commission (Union Register) · Mon 16 Nov 2026
- Pleasanton drug discovery firm Cyion to pay $528,336 over alleged False Claims Act grant violations HHS OIG · Mon 16 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.